While recent studies indicate that complete blockage of BACE1 activity may be associated with certain undesirable side-effects, important data demonstrates that partial reduction of BACE1 levels may improve cognitive deficits and amyloid neuropathology including Aβ deposition, at least in specific AD Tg models. The gene discussed is BACE1; the disease is Alzheimer disease.